- Home
- ELUT vs ICCM Comparison
ELUT vs ICCM Comparison
Compare ELUT & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ELUT | ICCM |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.3M | 41.4M |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ELUT | ICCM |
|---|---|---|
| Price | $1.06 | $0.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $6.00 | $2.50 |
| AVG Volume (30 Days) | 66.7K | ★ 619.8K |
| Earning Date | 05-08-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.77 | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $12,293,000.00 | N/A |
| Revenue This Year | N/A | $139.51 |
| Revenue Next Year | $10.83 | $75.66 |
| P/E Ratio | $1.23 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.27 |
| 52 Week High | $2.60 | $1.40 |
Technical Indicators
Market Signals| Indicator | ELUT | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 41.16 | 29.21 |
| Support Level | $1.00 | $0.28 |
| Resistance Level | $1.16 | $0.74 |
| Average True Range (ATR) | 0.06 | 0.03 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 2.94 | 11.33 |
Price Performance
Historical ComparisonAbout ELUT Elutia Inc.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.